Isomorphic Closes a 5 Billion Series C

Company Isomorphic Labs Event Type Series C financing ($5 billion) Modality AI drug design platform Asset IsoDDE platform; preclinical oncology and immunology candidates Target Multiple Disease Area Oncology; immunology Summary Isomorphic Labs announced a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *